ArticleJournal of neurosurgery. Case lessons2025
Extensive peritruncal subarachnoid hemorrhage: a risk factor for the development of spinal arachnoid cysts. Illustrative cases.
Article in Journal of neurosurgery. Case lessons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSpinal arachnoid cysts (SACs) are a rare, delayed complication after aneurysmal subarachnoid hemorrhage (aSAH), potentially leading to spinal cord injury. Pathogenesis and preventive strategies remain poorly understood, and management is often frustrating. The authors reviewed their institutional 19-year aSAH patient registry to explore SAC prevalence and potential risk factors. OBSERVATIONS: Among 1470 aSAH admissions (2005-2023), 1098 of whom were 6-month survivors, 5 patients (0.46%) developed symptomatic, imaging-confirmed SAC. All featured ruptured posterior circulation aneurysms with extensive peritruncal blood distribution, yielding an 11.4% SAC rate in this subgroup. In the authors' clinic, active blood clearance for aSAH therapy was introduced in October 2015. Notably, all SAC cases occurred in patients who did not receive active blood clearance (3 before October 2015 and 2 who were not eligible), resulting in a prevalence of 15.2%. The median time to myelopathy onset was 28 months (range 5-76 months). Four patients underwent surgery, but neurological deficits persisted; 1 patient still walked independently, 3 needed assistance, and 1 was nonambulatory. LESSONS: SACs may represent an underrecognized complication after aSAH, observed exclusively in patients with extensive peritruncal hemorrhage from posterior circulation aneurysms. The fact that all cases occurred in the absence of active blood clearance suggests a potential preventive role of this intervention. https://thejns.org/doi/10.3171/CASE25470.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.